Advertisement
Table 3 Effect of type of anaesthesia on the efficacy and safety of dabigatran etexilate: event rates observed with the different types of anaesthesia for each therapy
| Outcome | General anaesthesia | Neuraxial anaesthesia | Combination |
|---|---|---|---|
| Dabigatran etexilate 220 mg | |||
| Major VTE and VTE-related mortality | 4.0% (23/578) | 2.7% (29/1080) | 2.7% (10/369) |
| OR (95% CI) versus general anaesthesia | 0.67 (0.37–1.22) | 0.67 (0.28–1.49) | |
| MBE | 0.9% (7/785) | 1.7% (24/1379) | 1.4% (7/497) |
| OR (95% CI) versus general anaesthesia | 1.97 (0.82–5.43) | 1.59 (0.47–5.34) | |
| MBE/CRBE | 4.8% (38/785) | 5.9% (81/1379) | 6.0% (30/497) |
| OR (95% CI) versus general anaesthesia | 1.23 (0.82–1.87) | 1.26 (0.74–2.12) | |
| Dabigatran etexilate 150 mg | |||
| Major VTE and VTE-related mortality | 5.1% (30/587) | 3.2% (35/1082) | 3.3% (13/395) |
| OR (95% CI) versus general anaesthesia | 0.62 (0.37–1.06) | 0.63 (0.30–1.27) | |
| MBE | 1.3% (10/781) | 1.0% (14/1403) | 0.8% (4/530) |
| OR (95% CI) versus general anaesthesia | 0.78 (0.32–1.97) | 0.59 (0.13–2.05) | |
| MBE/CRBE | 5.4% (42/781) | 5.4% (76/1403) | 6.6% (35/530) |
| OR (95% CI) versus general anaesthesia | 1.01 (0.67–1.52) | 1.24 (0.76–2.03) | |
| Enoxaparin | |||
| Major VTE and VTE-related mortality | 3.5% (20/566) | 3.2% (37/1143) | 3.1% (12/383) |
| OR (95% CI) versus general anaesthesia | 0.91 (0.51–1.68) | 0.88 (0.39–1.92) | |
| MBE | 1.3% (10/745) | 1.5% (21/1430) | 1.6% (8/512) |
| OR (95% CI) versus general anaesthesia | 1.10 (0.49–2.62) | 1.17 (0.40–3.31) | |
| MBE/CRBE | 4.6% (34/745) | 5.6% (80/1430) | 4.5% (23/512) |
| OR (95% CI) versus general anaesthesia | 1.24 (0.81–1.93) | 0.98 (0.55–1.74) | |
